Skip to main content

MW 599.3 Da. PPADS, P2 purinergic receptor antagonist. Achieve your results faster with highly validated, pure and trusted compounds.

Be the first to review this product! Submit a review

Images

Chemical Structure - PPADS, P2 purinergic receptor antagonist (AB120009), expandable thumbnail
  • Cellular Activation - PPADS, P2 purinergic receptor antagonist (AB120009), expandable thumbnail
  • Functional Studies - PPADS, P2 purinergic receptor antagonist (AB120009), expandable thumbnail
  • Functional Studies - PPADS, P2 purinergic receptor antagonist (AB120009), expandable thumbnail

Publications

Key facts

CAS number

192575-19-2

Form

Solid

Molecular weight

599.3 Da

Molecular formula

C14H10N3Na4O12PS2

Nature

Synthetic

Recommended products

MW 599.3 Da. PPADS, P2 purinergic receptor antagonist. Achieve your results faster with highly validated, pure and trusted compounds.

Key facts

Solubility

Soluble in water to 100 mM.

Biochemical name

Ppads tetrasodium salt

Canonical SMILES

CC1=C(C(=C(C(=N1)N=NC2=C(C=C(C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])COP(=O)([O-])[O-])C=O)O.[Na+].[Na+].[Na+].[Na+]

IUPAC name

tetrasodium;4-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonatooxymethyl)pyridin-2-yl]diazenyl]benzene-1,3-disulfonate

Storage

Shipped at conditions

Ambient - Can Ship with Ice

Appropriate short-term storage conditions

-20°C

Appropriate long-term storage conditions

-20°C

Storage information

Store under desiccating conditions, The product can be stored for up to 12 months

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

  • Chemical Structure - PPADS, P2 purinergic receptor antagonist (ab120009), expandable thumbnail

    Chemical Structure - PPADS, P2 purinergic receptor antagonist (ab120009)

    2D chemical structure image of ab120009, PPADS, P2 purinergic receptor antagonist

  • Cellular Activation - PPADS, P2 purinergic receptor antagonist (ab120009), expandable thumbnail
    Image from Tchernookova B, et al. Plos One, 13(2), e0190893. Fig 2c,; doi: 10.1371/journal.pone.0190893

    Cellular Activation - PPADS, P2 purinergic receptor antagonist (ab120009)

    Inhibition by suramin and PPADS significantly reduces the ATP-induced increase in extracellular H+ flux from isolated Müller cells.
    Mean responses to 10 μM ATP with or without suramin and PPADS in the bath; N = 7, error bars represent SEMs.

  • Functional Studies - PPADS, P2 purinergic receptor antagonist (ab120009), expandable thumbnail
    Image from Gómez-Gonzalo M et al., PLoS Biol. 2010;8(4):e1000352. Fig 2.; doi: 10.1371/journal.pbio.1000352. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/

    Functional Studies - PPADS, P2 purinergic receptor antagonist (ab120009)

    Astrocyte Ca2+ signal inhibition does not affect interictal discharges.
    (A–D) Mean percentage of astrocytes activated by the ictal discharges (A), mean duration (B) and frequency (C) of the ictal discharge, and mean frequency of interictal discharges (D) under different experimental conditions in EC slice preparations. Controls (n=16), MPEP (MPEP hydrochloride, mGlu5 antagonist ab120008) (n=7), PPADS (ab120009) (n=9), and MPEP+PPADS (n=3). A single asterisk (*) indicates p<0.05; double asterisks (**), p<0.01.

  • Functional Studies - PPADS, P2 purinergic receptor antagonist (ab120009), expandable thumbnail
    Image from Gómez-Gonzalo M et al., PLoS Biol. 2010;8(4):e1000352. Fig 6(A).; doi: 10.1371/journal.pbio.1000352.

    Functional Studies - PPADS, P2 purinergic receptor antagonist (ab120009)

    Ca2+ signal from a field A neuron, a field B neuron, and field A astrocytes in response to repetitive episodes of NMDA stimulation (black arrowheads). The NMDA stimulation that evoked an ictal discharge became ineffective after blocking the astrocyte response by bath perfusion with MPEP (MPEP hydrochloride, mGlu5 antagonist ab120008) and PPADS (ab120009). An ictal discharge could be recovered by increasing the number of NMDA puffs (white arrowheads). A double NMDA pulse evoked both astrocyte activation and the ictal discharge after inhibitor washout.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com